151. Cytotoxic activity of Shp2 inhibitor fumosorinone in human cancer cells.
- Author
-
ChEN, Chuan, Xue, Tongdan, Fan, PENg, MENg, Linlin, Wei, Jingjing, and Luo, Duqiang
- Subjects
- *
FUNGAL proteins , *PHOSPHOTYROSINE , *CANCER cell growth , *ANTINEOPLASTIC agents , *CELL cycle regulation , *TUMOR treatment , *THERAPEUTICS , *PREVENTION - Abstract
Fumosorinone (Fumos) isolated from entomogenous fungi Isaria fumosorosea exhibited selective inhibition of Src homology phosphotyrosine phosphatase 2 inhibitor (Shp2) in our previous study. The purpose of the present study was to investigate the effects of Fumos on cell cycle arrest, tumor cell migration and the in vitro antiproliferative activity of Fumos alone or in combination with the commonly used cytotoxic drugs 5‑fluoracil (5‑FU) and p38 inhibitor SB203580. Fumos exhibited cytotoxicity against selected human cancel lines, including HeLa, MDA‑MB‑231 and MDA‑MB‑453 cell lines. Fumos exerted selective cytotoxic effects on the human cell lines. Flow cytometric and DAPI assays showed that Fumos did not induce cell apoptosis, however it induced cell cycle arrest at the G1 phase. Fumos inhibited cell migration though reducing the phosphorylation of focal adhesion kinase (FAK) at tyrosine (Tyr)861 and marginally increasing the phosphorylation of FAK at Tyr397, however, Fumos did not affect the phosphorylation of FAK at Tyr576 or Tyr925. The present study also examined the combination effect of Fumos with other chemical agents, including 5‑FU and p38 inhibitor SB203580. Fumos exhibited a marked synergistic effect with these agents, particularly with 5‑FU. In conclusion, Fumos showed potential anticancer bioactivity, and the combination effect of Fumos with 5‑FU or with p38 inhibitor offers a more effective anticancer strategy for carcinoma treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF